Our Vaccine Technologies

Harnessing innovation to protect lives in Africa and beyond.

*Next-gen vaccines — designed for impact, scaled for Africa.*

Why Vaccine Technology Matters

At LunaVax, we believe life-saving science should be accessible to everyone, everywhere. That’s why we develop next-generation vaccine platforms that are faster to produce, easier to scale, and tailored to meet the health needs of communities across Africa.

These innovations aren’t just about science—they’re how we close the global vaccine equity gap and build a healthier, more resilient future for all.

The Technologies We Use

1. mRNA Vaccines:

*mRNA strands — the digital blueprint guiding your body’s immune training.*

mRNA vaccines use a harmless genetic blueprint to teach your body how to fight viruses. They’re fast, adaptable, and proved their power during COVID-19. LunaVax is now advancing next-gen mRNA like saRNA for stronger, longer-lasting protection—perfect for low-resource settings.

Targeted Diseases: HPV, measles, malaria, polio, and rotavirus — with a focus on outbreak-prone infections in low-resource settings. Our mRNA platform is also being adapted based on its success during the COVID-19 pandemic.
Why We Use Them: Rapid development, precision targeting, and strong efficacy.

2. Viral Vector Vaccines:

*Viral vectors — harmless messengers delivering immunity instructions.*

These vaccines use safe, modified viruses (like adenoviruses) to deliver genetic instructions that spark immunity. They’ve protected against Ebola and show strong promise for diseases like tuberculosis and measles—especially where traditional options fall short.

Targeted Diseases: Tuberculosis, yellow fever, measles, and other candidates for future applications.
Why We Use Them: Proven platforms with strong immune activation.

3. DNA-Based Vaccines:

*DNA helix — a resilient twist in vaccine technology.*

DNA vaccines insert a snippet of genetic code that helps your body recognize and stop disease. They’re heat-stable, affordable, and easy to produce locally—making them ideal for areas with limited infrastructure.

Targeted Diseases: Hepatitis B, HPV, DTP (experimental), and potential applications in future emerging infections.
Why We Use Them: Heat-stable, scalable, and cost-effective—perfect for rural areas.

4. Protein Subunit Vaccines:

*Protein fragments — tiny pieces that pack a protective punch.*

These use small pieces of a virus (often proteins) to safely train your immune system. With a long track record in childhood vaccines, they’re a trusted, safe choice for children and immunocompromised people alike.

Targeted Diseases: DTP (diphtheria, tetanus, pertussis), Hib, pneumococcal disease, and hepatitis B.
Why We Use Them: Safe for children and immunocompromised patients.

How We Make Them

Our mission extends beyond research. We are building a resilient ecosystem for vaccine development through:

Local production facilities
Technology transfer partnerships
R&D collaboration for next-gen platforms like saRNA
Regional supply chain development
Sustainable manufacturing training
Alignment with national immunization goals

Why It Matters for Africa

*Science meets impact — bringing protection closer to every child, everywhere.*

90% of vaccines used in Africa are imported, making supply chains fragile. (WHO)
Fewer than 10 African countries have any local vaccine production capacity. (WHO)

LunaVax is changing that by tailoring technologies to fit Africa’s needs—building local resilience and empowering communities.

Join the Innovation

Let’s co-develop Africa’s next generation of vaccines—faster, fairer, and made for the continent.

Whether you’re a biotech innovator, funding organization, government agency, or academic partner—we welcome collaborators who believe in equitable healthcare solutions.

Explore Partnership Opportunities or Contact Us to shape the future of immunization.

Discover the Technologies Behind Our Vaccines